medical-device-investing NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
medical-device-investing NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
medical-device-investing NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
medical-device-investing NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society Annual Meeting
medical-device-investing NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
medical-device-investing NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
medical-device-investing NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
Valeura Energy: Positioned for Organic Growth and Accretive M&A in Southeast Asia’s Offshore Oil Sector
